

INTERIM FORMULARY UPDATE

The following recommendations, made at the June 12, 2009 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Ondansetron	Zofran [®]	Tablet: 4 mg, 8 mg Tablet, oral disintegrating: 4 mg, 8 mg	Central Nervous System, Antiemetic/ Antivertigo Agents

Product(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Sectional Review for Anti-Parkinson Agents:

Generic Name	Brand Name	Dosage Form	Classification
Rasagiline	Azilect [®]	Tablet: 0.5 mg, 1 mg	Central Nervous System, Antiparkinson Agents

Dosage strength/formulations **recommended to be deleted** from the DADS/DSHS Drug Formulary based on the Sectional Review for Anti-Parkinson Agents:

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
Biperiden	Akineton	Tablet 2 mg	None

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on an additional review of the Formulary:

- Clonazepam (Klonopin[®])
 - Oral disintegrating tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg
- Vitamin D
 - Tablet: 2,000 Units
 - Capsule: 2,000U
- Venlafaxine
 - Extended release tablet: 3.75 mg, 75 mg, 150 mg, 225 mg

Approved:



Ann Richards, Phram.D. BCPP
Pharmacy Services Director, San Antonio State Hospital

July 16, 2009

Date: